



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Volociximab

Cat. No.:	HY-P99333
CAS No.:	558480-40-3
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin $\alpha 5\beta 1$ ( $EC_{50}=0.2$ nM). Integrin $\alpha 5\beta 1$ is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	$\alpha 5\beta 1$ 0.2 nM (EC <sub>50</sub> )
<b>In Vitro</b>	Volociximab (20, 40, 80, 160, 320 nM) specifically targets integrin $\alpha 5\beta 1$ ( $K_d=0.367$ nM), but not integrin $\alpha 5\alpha 5$ or $\beta 1\beta 1$ <sup>[1]</sup> . Volociximab (0.01-100 nM; 4 d) inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVEC) (IC <sub>50</sub> =0.2-0.5 nM) and (10 $\mu$ g/mL; 16 h) induces apoptosis in schizogenic but not senescent Huvecs <sup>[1]</sup> . Volociximab (0.067-67 nM; 6 d) inhibits 0.1 $\mu$ g/mL VEGF and/or bFGF induced HUVEC angiogenesis in vitro <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Volociximab (300 $\mu$ g/eye; intravitreal injection; once weekly for 4 weeks) has well tolerance and inhibits angiogenesis in laser induced choroidal neovascularization (CNV) of cynomolgus monkey model <sup>[1]</sup> . Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Bhaskar V, et al. Volociximab, a chimeric integrin  $\alpha 5\beta 1$  antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12.
- [2]. Ramakrishnan V, et al. Preclinical evaluation of an anti- $\alpha 5\beta 1$  integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA